Engagement
A strategic functional precision oncology programme focused on introducing OptimAI™ to the Turkish clinical and research ecosystem and building locally relevant translational evidence.
Approach
Patient-derived tumour models and ex vivo drug-response profiling are integrated with AI-supported analysis to evaluate therapeutic sensitivity, resistance patterns and clinically relevant treatment combinations. The collaboration also extends to clinical and scientific validation, model development and joint translational research.
Scope
- Functional precision medicine
- Patient-derived tumour models
- Ex vivo drug-response profiling
- AI-supported therapeutic prioritization
- Clinical validation
- Translational oncology
Where
Singapore × Türkiye
- Precision Oncology
- Patient-Derived Models
- Functional Precision Medicine
- AI-Supported Analysis